LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Abierto

1.25 -1.57

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.22

Máximo

1.28

Métricas clave
By Trading Economics
Ingresos	17M -26M
Empleados	171
EBITDA	19M -23M

Recomendaciones
By TipRanks
Recomendaciones	Vender
Estimación a 12 Meses	+53.85% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-27M 76M
Apertura anterior	2.82
Cierre anterior	1.25

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 mar 2026, 23:41 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2 mar 2026, 23:37 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2 mar 2026, 23:26 UTC

Noticias de Eventos Importantes

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2 mar 2026, 22:41 UTC

Charlas de Mercado

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2 mar 2026, 22:32 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 22:32 UTC

Charlas de Mercado

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2 mar 2026, 22:21 UTC

Charlas de Mercado

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2 mar 2026, 22:11 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 mar 2026, 22:11 UTC

Charlas de Mercado

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2 mar 2026, 22:10 UTC

Adquisiciones, fusiones, absorciones

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2 mar 2026, 22:06 UTC

Charlas de Mercado

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2 mar 2026, 22:00 UTC

Charlas de Mercado

Ganancias

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 22:00 UTC

Charlas de Mercado

Ganancias

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2 mar 2026, 21:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Energy & Utilities Roundup: Market Talk

2 mar 2026, 21:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

2 mar 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

2 mar 2026, 21:35 UTC

Adquisiciones, fusiones, absorciones

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2 mar 2026, 21:34 UTC

Adquisiciones, fusiones, absorciones

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2 mar 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2 mar 2026, 21:17 UTC

Noticias de Eventos Importantes

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2 mar 2026, 20:44 UTC

Ganancias

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2 mar 2026, 20:43 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Treasury Yields Rise, Dollar Strengthens After Attack on Iran -- Market Talk

2 mar 2026, 20:28 UTC

Ganancias

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2 mar 2026, 20:25 UTC

Charlas de Mercado

Noticias de Eventos Importantes

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2 mar 2026, 20:24 UTC

Ganancias

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2 mar 2026, 20:14 UTC

Adquisiciones, fusiones, absorciones

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2 mar 2026, 20:12 UTC

Noticias de Eventos Importantes

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2 mar 2026, 20:08 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 20:08 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2 mar 2026, 20:05 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

53.85% repunte

Estimación a 12 Meses

Media 2 USD 53.85%

Máximo 2 USD

Mínimo 2 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Vender

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.